PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-4.83%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-4.74%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-11.58%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-25.27%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-11.81%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-11.81%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-11.81%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-0.00%
Share reduction while 3088.T is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 3088.T is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
44.88%
10Y revenue/share CAGR above 1.5x 3088.T's 28.84%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
-7.45%
Negative 5Y CAGR while 3088.T stands at 21.30%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
38.84%
3Y revenue/share CAGR above 1.5x 3088.T's 10.39%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
194.01%
Net income/share CAGR 1.25-1.5x 3088.T's 154.55%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
16.46%
Below 50% of 3088.T's 82.55%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
59.57%
3Y net income/share CAGR 1.25-1.5x 3088.T's 50.42%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
131.98%
Equity/share CAGR of 131.98% while 3088.T is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
27.65%
Below 50% of 3088.T's 61.01%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
68.35%
3Y equity/share CAGR above 1.5x 3088.T's 21.96%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
-2.78%
Negative 5Y dividend/share CAGR while 3088.T stands at 350.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-30.00%
Negative near-term dividend growth while 3088.T invests at 50.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
-12.20%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
6.37%
Inventory growth well above 3088.T's 0.01%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
1.87%
Asset growth above 1.5x 3088.T's 1.18%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
5.11%
BV/share growth above 1.5x 3088.T's 0.59%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-6.73%
We’re deleveraging while 3088.T stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
2.77%
SG&A growth well above 3088.T's 0.21%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.